Session Type
Meeting
Search Results for thromboembolism
Abstract Number: 119
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Prophylactic anticoagulation is effective at reducing the risk of venous thromboembolism (VTE), but can also increase the risk of bleeding. Whether anticoagulant prophylaxis should be modified for underweight patients to minimize bleeding complications is unknown. We sought to determine whether being underweight is associated with the risk of major bleeding in hospitalized medical patients […]
Abstract Number: 129
Hospital Medicine 2020, Virtual Competition
Background: Cancer-associated thrombosis (CAT) is a common complication in patients with malignancy. Management of venous thromboembolism (VTE), in these patients, is challenging due to the high risk of recurrence and inherent risk of bleeding in this population. Direct oral anticoagulants (DOACs) have emerged as a treatment options for CAT. As yet there have not been […]
Abstract Number: 143
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Multi-lumen (ML) peripherally inserted central catheters (PICCs) are associated with increased risk of central line associated blood stream infection (CLABSI), venous thromboembolism (VTE) and increased cost compared to single lumen (SL) PICCs. Current guidelines recommend minimizing the number of PICC lumens. However, there is a paucity of literature to guide the selection of SL […]
Abstract Number: 144
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 145
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 154
Hospital Medicine 2020, Virtual Competition
Background: Increased risk of venous thromboembolism (VTE) has been noted among cancer patients as compared to non-cancer. Cancer associated thrombosis caused three folds increased hospitalizations, increased inpatient/outpatient medical and prescription claims, and increased total health care costs per patient. Our objective was to study demographic, clinical and laboratory risk factors for venous thromboembolism (VTE) among […]
Abstract Number: 173
SHM Converge 2023
Background: In-hospital venous thromboembolism (VTE) remains an important preventable cause of morbidity/mortality. Multiple risk assessment models (RAMs) for VTE in hospitalized medical patients have been developed, validated, and endorsed by several national societies. Despite evidence and guidelines supporting risk stratification for VTE prevention, data suggest that prophylactic measures are not appropriately utilized. In a nation-wide […]
Abstract Number: 180
Hospital Medicine 2020, Virtual Competition
Background: Peripherally inserted central catheters (PICCs) are associated with an increased risk of central line-associated bloodstream infection (CLABSI) and venous thromboembolism (VTE). Catheters that are coated or impregnated with antimicrobial and/or antithrombotic agents have been developed to prevent these complications. However, their effectiveness in preventing CLABSI and VTE is unclear. Using data from a large […]
Abstract Number: 181
SHM Converge 2021
Background: Venous thromboembolism (VTE) is a significant cause of morbidity and mortality for hospitalized patients. There are approximately 900,000 new VTE events and 100,000 VTE-related deaths every year. In the United States, more deaths occur due to VTE than breast cancer, AIDS, and motor vehicle accidents combined. VTE are considered preventable events with appropriate prophylaxis; […]
Abstract Number: 182
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Compared with patients in the community, patients acutely hospitalized are at higher risk of developing venous thromboembolism (VTE), contributing to patient morbidity and mortality and healthcare costs. The need for thromboprophylaxis for post-surgical patients is well-known and the importance of thromboprophylaxis for acutely-ill hospitalized medicine patients has been increasingly accepted. We aimed to analyze […]